Therapeutic peptides and peptidomimetics

Current Opinion in Biotechnology

Volumn 8, Issue 4, 1997, Pages 435-441

  Kieber Emmons, Thomas ^a   Murali, Ramachandran ^a   Greene, Mark I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BIOTECHNOLOGY; CYCLIZATION; DNA LIBRARY; DRUG DESIGN; LIGAND BINDING; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0030752336     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80065-1     Document Type: Article

References (56)

1. Jones TK, Pathirana C, Goldman ME, Hamann LG, Farmer LJ, Ianiro T, Johnson MG, Bender SL, Mais DE, Stein RB: Discovery of novel intracellular receptor modulating drugs. J Steroid Biochem Mol Biol 1996, 56:61-66. General review paper covering the identification of small molecule intracellular hPR modulators.
2. Shaver A, Ng JB, Hall DA, Posner BI: The chemistry of peroxovanadium compounds relevant to insulin mimesis. Mol Cell Biochem 1995, 153:5-15.
3. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA: Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8Ȧ. Science 1996, 273:464-471. This paper provides the first structural example of functional mimicry of a hormone by a cyclic peptide.
4. Malley MF, Tabernero L, Chang CY, Ohringer SL, Roberts DG, Das J, Sack JS: Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090. Protein Sci 1996, 5:221-228.
5. Zhao B, Helms LR, DesJarlais RL, Abdel MS, Wetzel R: A paradigm for drug discovery using a conformation from the crystal structure of a presentation scaffold. Nat Struct Biol 1995, 2:1131-1137.
6. Li J, Cook R, Dede K, Chaiken I: Single chain human interleukin 5 and its asymmetric mutagenesis for mapping receptor binding sites. J Biol Chem 1996, 271:1817-1820.
7. Li B, Tom JY, Oare D, Yen R, Fairbrother WJ, Wells JA, Cunningham BC: Minimization of a polypeptide hormone. Science 1995, 270:1657-1660.
8. Hirschmann R, Yao W, Cascieri MA, Strader CD, Maechler L, Cichy-Knight MA, Hynes J Jr, van Rijn RD, Sprengler PA, Smith AB III: Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic. J Med Chem 1996, 39:2441-2448. This paper emphasizes a minilibrary/design strategy to develop the first potent, selective cyclic hexapeptide ligand for the NK-1 receptor.
9. Gui J, Moyana T, Xiang J: Selection of a peptide with affinity for the tumor-associated TAG72 antigen from a phage-displayed library. Biochem Biophys Res Commun 1996, 218:414-419.
10. Horwell DC: The 'peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides. Trends Biotechnol 1995, 13:132-134.
11. Bevan P, Ryder H, Shaw I: Identifying small-molecule lead compounds: the screening approach to drug discovery. Trends Biotechnol 1995, 13:115-121.
12. Kleinberg ML, Wanke LA: New approaches and technologies in drug design and discovery. Am J Health Syst Pharm 1995, 52:1323-1336.
13. Cho MJ, Juliano R: Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations. Trends Biotechnol 1996, 14:153-158. A good general review paper on small molecule development, emphasizing clinical concepts in the process.
14. Cheng S, Tarby CM, Comer DD, Williams JP, Caporale LH, Myers PL, Boger DL: A solution-phase strategy for the synthesis of chemical libraries containing small organic molecules: a universal and dipeptide mimetic template. Bioorgan Med Chem 1996, 4:727-737. A general approach to the solution phase, parallel synthesis of chemical libraries, exemplifying both a universal and dipeptide mimetic template.
15. McBride JD, Freeman N, Domingo GJ, Leatherbarrow RJ: Selection of chymotrypsin inhibitors from a conformationally-constrained combinatorial peptide library. J Mol Biol 1996, 259:819-827. This paper shows that directed randomization of a canonical protein-derived loop region is a powerful way of generating proteinase inhibitors with targeted specifities.
16. Zhang WJ, Nikiforovich GV, Perodin J, Richard DE, Escher E, Marshall GR: Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications. J Med Chem 1996, 39:2738-2744.
17. Beusen DD, Zabrocki J, Slomczynska U, Head RD, Kao JL, Marshall GR: Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate. Biopolymers 1995, 36:181-200.
18. Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ: The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors. J Med Chem 1996, 39:4120-4124.
19. Howl J, Wheatley M: Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors. Biochem J 1996, 317:577-582.
20. Reid RC, March DR, Dooley MJ, Bergman DA, Abbenante G, Fairlie DP: A novel bicyclic enzyme-inhibitor as a consensus peptidomimetic for the receptor-bound conformations of 12 peptidic inhibitors of HIV-1 protease. J Am Chem Soc 1996, 118:8511-8517. An excellent example of using structural information in the rational design of bicyclics that fix receptor-bound conformations of bioactive peptides.
21. Tong L, Pav S, Lamarre D, Simoneau B, Lavallee P, Jung G: Crystallographic studies on the binding modes of P2-P3 butanediamide renin inhibitors. J Biol Chem 1995, 270:29520-29524.
22. Chao TM, Perez JJ, Loew GH: Characterization of the bioactive form of linear peptide antagonists at the omega-opioid receptor. Biopolymers 1996, 38:759-768. A good example of theoretical conformational studies and the role played by amino acid residues at particular positions.
23. Ladner RC: Constrained peptide as binding entities. Trends Biotechnol 1995, 13:426-430.
24. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273:458-464. An excellent example of how random phage display peptide libraries and affinity selective methods can be used to isolate small peptides that bind to and activate a receptor.
25. Monfardini C, Kieber-Emmons T, Voet D, Godillot AP, Weiner DB, Williams WV: Rational design of granulocyte-macrophage colony-stimulating factor antagonist peptides. J Biol Chem 1996, 271:2966-2971. This paper suggests strategies for mimicking binding sites on four-helix bundle proteins with cyclic peptides.
26. LeSauteur L, Wei L, Gibbs BF, Saragovi HU: Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. J Biol Chem 1995, 270:6564-6569.
27. Banerjee A, Pramanik A, Bhattacharjya S, Balaram P: Omega-amino acids in peptide design: incorporation into helices. Biopolymers 1996, 39:769-777.
28. Javadpour MM, Juban MM, Lo WC, Bishop SM, Aberty JB, Cowell SM, Becker CL, McLaughlin ML: De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 1996, 39:3107-3113. This paper suggests that de novo considerations in peptide development can lead to bioactive peptides.
29. Demoor L, Boutillon C, Fievet C, Vanloo B, Baert J, Rosseneu M, Fruchart JC, Tartar A: Branched synthetic constructs that mimic the physico-chemical properties of apolipoprotein Al in reconstituted high-density lipoproteins. Eur J Biochem 1996, 239:74-84. This paper provides evidence for the increased abilities of multimeric peptides to associate with phospholipids compared with the short linear peptides, constituting an alternative approach to linear peptides, which are typically poor mimics.
30. Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M: Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 1995, 37:57-66.
31. Abbenante G, Bergman DA, Brinkworth RI, March DR, Reid RC, Hunt PA, James IW, Dancer RJ, Garnham B, Stoermer ML, Fairlie DP: Structure-activity-relationships for macrocyclic peptidomimetic inhibitors of HIV-1 protease Bioorgan Med Chem Lett 1996, 6:2531-2536.
32. Barchi JJ Jr, Nomizu M, Otaka A, Roller PP, Burke TR Jr: Conformational analysis of cyclic hexapeptides designed as constrained ligands for the SH2 domain of the p85 subunit of phosphatidylinositol-3-OH kinase. Biopolymers 1996, 38:191-208. A very detailed study using NMR, calculations and assays to elucidate structure/function relationships.
33. McDonnell JM, Beavil AJ, Mackay GA, Jameson BA, Korngold R, Gould HJ, Sutton BJ: Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor. Nat Struct Biol 1996, 3:419-426.
34. Chorev M, Goodman M: Recent developments in retro peptides and proteins - an ongoing topochemical exploration. Trends Biotechnol 1995, 13:438-445.
35. Oliyai R: Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv Drug Del Rev 1996, 19:275-286. This paper is an excellent review of the utility of prodrugs to circumvent the obstacles associated with delivery and formulation of peptides and peptidomimetics.
36. Greene DL, Hau VS, Abbruscato TJ, Bartosz H, Misicka A, Lipkowski AW, Hom S, Gillespie TJ, Hruby VJ, Davis TP: Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability. J Pharmacol Exp Ther 1996, 277:1366-1375. This paper provides a good example of the importance of residue placement in the peptide backbone and lipophilicity for membrane association.
37. Zhang X, Piatiertonneau D, Auffray C, Murali R, Mahapatra A, Zhang FQ, Maier CC, Saragovi H, Greene MI: Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T-cell activation. Nat Biotechnol 1996, 14:472-475. This paper suggests a strategy for creating novel synthetic antagonistic receptor complexes using self-peptides, representing a new receptor specific pharmaceutical approach to modulate biological function.
38. Zhang X, Gaubin M, Briant L, Srikantam V, Murali R, Saragovi U, Weiner D, Devaux C, Auterio M, Piatiertonneau D, Greene MI: Synthetic CD4 exocyclics inhibit binding of human-immunodeficiency-virus type-1 envelope to CD4 and virus-replication in T-lymphocytes. Nat Biotechnol 1997, 15:150-154. This paper provides an example of how exocyclic compounds based on the structure of a native protein can impair virus binding.
39. Zhang YL, Dawe AL, Jiang Y, Becker JM, Naider F: A superactive peptidomimetic analog of a farnesylated dodecapeptide yeast pheromone. Biochem Biophys Res Commun 1996, 224:327-331.
40. Pueyo C, Badimon JJ, Royo T, Feigen LP, Badimon L: A mimetic of the RGDF-peptide [arginine-glycine-aspartic acid-phenylalanine] blocks aggregation and flow-induced platelet deposition on severely injured stenotic arterial wall. Effects on different animal models and in humans. Thromb Res 1996, 81:101-112.
41. Ojima I, Chakravarty S, Dong Q: Antithrombotic agents: from RGD to peptide mimetics. Bioorg Med Chem 1995, 3:337-360.
42. Somjen D, Amir-Zaltsman Y, Mor G, Gayer B, Lichter S, Barnard G, Kohen F: Anti-idiotypic antibody as an oestrogen mimetic in vivo: stimulation of creatine kinase specific activity in rat animal models. J Endocrinol 1996, 149:305-312.
43. Magliani W, Conti S, De Bernardis F, Gerloni M, Bertolotti D, Mozzoni P, Cassone A, Polonelli L: Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat Biotechnol 1997, 15:155-158. A good example of how recombinant antibody fragments can have potential therapeutic applications.
44. Smithgall TE: SH2 and SH3 domains: potential targets for anti-cancer drug design. J Pharmacol Toxicol Methods 1995, 34:125-132.
45. Burke TJ, Barchi JJ, George C, Wolf G, Shoelson SE, Yan X: Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors. Med Chem 1995, 38:1386-1396.
46. Levy R: [Farnesyl transferase inhibitors (anti-Ras). A new class of anticancer agents]. Presse Med 1995, 24:725-729.
47. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD et al.: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995, 270:26802-26806.
48. McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogi A, Hamilton AD et al.: CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. Biochem Biophys Res Commun 1995, 214:295-303.
49. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 1995, 55:5310-5314.
50. Bishop WR, Bond R, Petrin J, Wang L, Patton R, Doll R, Njoroge G, Catino J, Schwartz J, Windsor W et al.: Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells. J Biol Chem 1995, 270:30611-30618.
51. Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD, Carthew RW: Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proc Natl Acad Sci USA 1995, 92:10919-10923.
52. Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM: A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J Biol Chem 1995, 270:660-664.
53. Westerink MA, Giardina PC, Apicella MA, Kieber-Emmons T: Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc Natl Acad Sci USA 1995, 92:4021-4025.
54. Kieber-Emmons T, Luo P, Agadjanyan M, Hutchins W, Westreink M, Steplewski Z: Peptide mimicry of adenocarcinoma-associated carbohydrate antigens. Hybridoma 1997, 16:3-10.
55. Agadjanyan M, Lou P, Westerink MAJ, Carey LA, Hutchins W, Stepewski Z, Weiner DB, Kieber-Emmons T: Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat Biotechnol 1997, 15:547-551. A compelling manuscript showing that peptides that mimic associated and histo-blood group carbohydrate antigens can induce polyclonal immune responses in experimental animals that neutralize HIV in vitro.
56. Das J, Kimball SD: Thrombin active site inhibitors. Bioorg Med Chem 1995, 3:999-1007.